



## **Supplementary Materials**

### **Uncovering flavivirus host dependency factors through a genome-wide gain-of-function screen**


Evgeniya Petrova, Ségolène Gracias, Guillaume Beauclair, Frédéric Tangy, and Nolwenn Jouvenet




**Fig. S1. Validation of siRNA-mediated gene silencing.** Validation of siRNA-mediated gene silencing by RT-qPCR 48 hours after siRNA transfection of HeLa cells. Data are represented as mean  $\pm$  SD of three independent experiments. Significance was calculated using a one-way ANOVA test of comparisons to control siRNA-transfected samples.




**Fig. S2. Cell viability determination following siRNA-mediated RPL19 silencing.** Percent viability of HeLa (A) or A549 (B) cells determined by trypan blue exclusion assays 48 hours after transfection with siRNA. Data are represented as mean  $\pm$  SD of three independent experiments.



**Fig. S3. Silencing of RPL19 does not affect early stages of YFV replication.** HeLa cells were transfected with siRNA targeting RPL19 or ATP6V1B2 and 48 hours later infected with YFV at a MOI of 1. The relative amounts of cell-associated viral RNA were determined by qPCR analysis at 6 hours post-infection. Amounts of viral RNA are expressed as genome equivalents (GE) per µg of total RNA. Data are represented as mean  $\pm$  SD of three independent experiments. Significance was calculated using a one-way ANOVA test of comparisons to control siRNA-transfected samples.



**Fig. S4. Validating the role of RPL19 on viral replication by an over-expression approach.** (A) Validation of gene over-expression in HT1080 stable cell lines by RT-qPCR. The results are expressed in RNA copies/ $\mu\text{g}$  of total RNA and are represented as mean  $\pm$  SD of three independent experiments. (B) Replicon assays were performed with YFV/WNV chimeric RVPs in HT1080 cell lines over-expressing RPL19, RPS3, DDOST or TIM-1. Median Fluorescence Intensity (MFI) of GFP positive cells were determined by flow cytometry analysis 48 hours post-infection and normalized to cells transduced with an empty vector. Data are represented as mean  $\pm$  SD of at least three independent experiments. Significance was calculated using one-way ANOVA tests of comparisons to empty vector cell line.



**Fig. S5. Cell viability determination following siRNA-mediated ribosomal gene silencing and validation of gene silencing efficiency.** (A) Comparison of gene silencing efficiency between two different siRNA oligos and a pool of siRNA oligos in HeLa cells. mRNA expression level of silenced genes was determined by RT-qPCR 48 hours post-transfection. (B) Percent viability of HeLa cells determined by trypan blue exclusion assay 48 hours after transfection with siRNA. Data are represented as mean  $\pm$  SD of three independent experiments.

Target	Provider	siRNA type, reference number
Non-targeting control	ThermoFischerScientific	Silencer® Select Negative control No.1 siRNA, 4390843
	Dharmacon	ON-TARGETplus SMARTpool, D-001810-10
GAPDH	Dharmacon	ON-TARGETplus SMARTpool, D-001830-10
RPL19	ThermoFischerScientific	Silencer® Select Pre-Designed siRNA, ID: s12183
		Silencer® Select Pre-Designed siRNA, ID: s226957
RPS3	ThermoFischerScientific	Silencer® Select Pre-Designed siRNA, ID: s12255
		Silencer® Select Pre-Designed siRNA, ID: s12256
		Silencer® Select Pre-Designed siRNA, ID: s25032
GIGYF2	ThermoFischerScientific	Silencer® Select Pre-Designed siRNA, ID: s25033
		Silencer® Select Pre-Designed siRNA, ID: s25034
	Dharmacon	ON-TARGETplus SMARTpool, L-013918-01
DDOST	ThermoFischerScientific	Silencer® Select Pre-Designed siRNA, ID: 3999
	Dharmacon	ON-TARGETplus SMARTpool, L-015786-01
TIMP4	Dharmacon	ON-TARGETplus SMARTpool, L-011406-00
IPO9	ThermoFischerScientific	Silencer® Select Pre-Designed siRNA, ID: 31300
ATP6V1B2	ThermoFischerScientific	Silencer® Select Pre-Designed siRNA, ID: 7178
		Silencer® Select Pre-Designed siRNA, ID: 112786
RPS25	ThermoFischerScientific	Silencer® Select Pre-Designed siRNA, ID: s12336
		Silencer® Select Pre-Designed siRNA, ID: s53506
RACK1	ThermoFischerScientific	Silencer® Select Pre-Designed siRNA, ID: s20340
		Silencer® Select Pre-Designed siRNA, ID: s20341

**Table S1.** siRNA oligos used for gene silencing experiments.

Target	Primer	DNA sequence, 5'-3'
		<i>attB1/attB2 sequence, gene-specific sequence</i>
RPL19	forward	<u>GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACC</u> <i>ATGAGTATGCTCAGGCTTCAG</i>
	reverse	<u>GGGGACCACTTTGTACAAGAAAGCTGGGTTTTATTATTTCTTGGTCTCTTCCTCCT</u>
RPS3	forward	<u>GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACC</u> <i>ATGGCAGTGCAAATATCCAAGAAG</i>
	reverse	<u>GGGGACCACTTTGTACAAGAAAGCTGGGTTTTATTATGCTGTGGGGACTGGCT</u>
TIM1	forward	<u>GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACC</u> <i>ATGCATCCTCAAGTGGTC</i>
	reverse	<u>GGGGACCACTTTGTACAAGAAAGCTGGGTTTTATTAGTCCGTGGCATAAAGACTATTCTC</u>

**Table S2.** DNA sequence of primers used for cloning.



Target	Primer	DNA sequence, 5'- 3'	Reference
YFV NS3	forward	GCGTAAGGCTGGAAAGAGTG	-
	reverse	CTTCCTCCCTTCATCCACAA	
WNV Capsid	forward	CCGCGTGTTGTCCTTGATT	Fernandez-Garcia et al., 2010
	reverse	GCCCCTTGCCGTCGAT	
ZIKV NS5	forward	AARTACACATAACCARAACAAAGTGGT	Faye et al., 2013
	reverse	TCCRCTCCCYCTYTGGTCTTG	
GAPDH	forward	GGTCGGAGTCAACGGATTTG	-
	reverse	ACTCCACGACGTACTCAGCG	
RPL19	forward	GGGCATAGGTAAGCGGAAGG	Bee et al., 2011
	reverse	TCAGGTACAGGCTGTGATACA	
RPS3	forward	GCGAGTTACACCAACCAGGA	-
	reverse	CCCTCTGGAAAGCCAAACCT	
GIGYF2	forward	ACGCAGACACTGAACTTTGG	-
	reverse	CATTTCTTCTCTGCCGTAACGA	
DDOST	forward	CCGACATTGGTGACCCTCTTC	-
	reverse	TCAGCCACGATGAGCGTATG	
TIMP4	forward	AACTGTGGCTGCCAAATCAC	-
	reverse	GCTTTCGTTCCAACAGCCAG	
ATP6V1B2	forward	GAGGGGCAGATCTATGTGGA	Coffey et al., 2014
	reverse	GCATGATCCTTCCTGGTCAT	
RPS25	forward	GGACGACAAGAAGAAGAAGGAC	-
	reverse	GAACCTTGCCTTTGGACCACT	
RACK1	forward	TAACCGCTACTGGCTGTGTG	-
	reverse	GTTCTGCCTTGCTGCTGGTA	
IPO9	forward	AGATGTTGGTGAGCGGAGAC	-
	reverse	CTGGGAGAATGACAGGAGCA	
TIM1	forward	CCAGTAGCCACTTCACCATCTTCAC	Zhao et al, 2010
	reverse	CGGTGTCATTCCCATCTGTTGTG	

**Table S3.** DNA sequence of primers used for real-time qPCR.